GH Research (NASDAQ:GHRS) Shares Gap Up – Here’s What Happened

GH Research PLC (NASDAQ:GHRS) shares gapped up before the market opened on Thursday . The stock had previously closed at $11.35, but opened at $11.75. GH Research shares last traded at $11.14, with a volume of 18,497 shares.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Stifel Nicolaus upped their price target on GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Cantor Fitzgerald began coverage on GH Research in a research note on Thursday, February 13th. They set an “overweight” rating and a $14.00 target price for the company. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a research note on Monday, January 27th. Canaccord Genuity Group decreased their target price on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, Guggenheim began coverage on GH Research in a research note on Thursday. They set a “buy” rating and a $32.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, GH Research presently has an average rating of “Buy” and a consensus target price of $30.86.

GH Research Trading Down 4.2 %

The firm has a fifty day simple moving average of $11.03 and a 200 day simple moving average of $9.18. The stock has a market cap of $565.49 million, a price-to-earnings ratio of -13.73 and a beta of 0.94.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. On average, equities analysts expect that GH Research PLC will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

A number of hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. raised its holdings in shares of GH Research by 1.3% in the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock worth $44,734,000 after buying an additional 85,000 shares in the last quarter. Lynx1 Capital Management LP raised its holdings in shares of GH Research by 15.8% in the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after buying an additional 663,100 shares in the last quarter. Diadema Partners LP acquired a new stake in GH Research during the 4th quarter valued at $711,000. Woodline Partners LP increased its holdings in GH Research by 112.0% during the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock valued at $553,000 after purchasing an additional 41,711 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after purchasing an additional 3,092 shares in the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).